Table 3 Response criteria of each latent class identified.

From: Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis

 

Lithe cohort

Class 1

Class 2

Class 3

P value

N

485

85

338

62

 

% ACR response

ACR20 (week 24)

256 (52.8)

36 (42.3)

166 (49.1)

54 (87.1)

< 0.001

ACR50 (week 24)

142 (29.3)

10 (11.7)

93 (27.5)

39 (62.9)

< 0.001

ACR70 (week 24)

64 (13.2)

3 (3.5)

36 (10.6)

25 (40.3)

< 0.001

ACR20 (week 52)

238 (49.1)

29 (34.1)

158 (46.7)

51 (82.3)

< 0.001

ACR50 (week 52)

150 (30.9)

9 (10.6)

98 (28.9)

43 (69.4)

< 0.001

ACR70 (week 52)

89 (18.3)

2 (2.4)

51 (15.1)

36 (58.1)

< 0.001

Escape therapy

< 0.001

Yes

99 (20.4)

38 (30.2)

59 (19.1)

2 (3.9)

 

No

387 (79.6)

88 (69.8)

250 (80.9)

49 (96.1)

 

EULAR response (week 24)*

< 0.001

No response

37 (10.1)

17 (16.4)

19 (10.6)

1 (1.8)

 

Mod. response

170 (46.7)

57 (70.5)

105 (46.7)

8 (19.6)

 

Good response

157 (43.1)

7 (13.1)

112 (42.7)

38 (78.6)

 

EULAR activity (week 24)*

< 0.001

High

60 (16.3)

21 (33.3)

38 (15.3)

1 (1.8)

 

Moderate

148 (40.1)

33 (52.4)

104 (41.8)

11 (19.3)

 

Low

188 (19.5)

28 (11.1)

143 (21.3)

17 (21.1)

 

Remission

89 (24.1)

2 (3.2)

54 (21.7)

33 (57.9)

 
  1. *Patients with missing measurements due to lack of sample or receiving escape therapy did not have a change in DAS28 calculated and were therefore omitted from this analysis.
  2. Response criteria fulfilled by each latent class trajectory. Data presented as n (%) unless indicated otherwise. In the case data was missing, this was omitted from analysis.